Cargando…
SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis
Autores principales: | Tuncay, Gülseren, Bostan, Ozge Can, Damadoglu, Ebru, Karakaya, Gül, Kalyoncu, Ali Fuat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894735/ https://www.ncbi.nlm.nih.gov/pubmed/35257871 http://dx.doi.org/10.1016/j.anai.2022.02.026 |
Ejemplares similares
-
A practical method of drug provocation testing to prove tolerance to alternative drugs in drug hypersensitivity
por: DAMADOĞLU, Ebru, et al.
Publicado: (2021) -
Cytokine Profiles of Chronic Urticaria Patients and The Effect of Omalizumab Treatment
por: Can Bostan, Ozge, et al.
Publicado: (2023) -
Clinical Validation of the Spirohome Clinic Ultrasonic Spirometer in Child and Adolescent Patients
por: Sekerel, Bulent Enis, et al.
Publicado: (2022) -
COVID-19 vaccination in the setting of mastocytosis—Pfizer-BioNTech mRNA vaccine is safe and well tolerated
por: Lazarinis, Nikolaos, et al.
Publicado: (2022) -
Response to the letter to the editor: two cases of subacute thyroiditis after different types of SARS-CoV-2 vaccination
por: Bostan, Hayri, et al.
Publicado: (2022)